<DOC>
	<DOCNO>NCT00509028</DOCNO>
	<brief_summary>This study include patient Japanese child bronchial asthma age 5 year 15 year old complete Phase III study ( Study code : D5254C00769 ) 29 centre . To investigate safety budesonide Turbuhaler® daily dose 100 µg 800 µg 54 week treatment include prior 6 week Phase III study ( Study D5254C00769 , NCT00504062 ) compare conventional therapy Japanese child bronchial asthma need inhale glucocorticosteroid treatment .</brief_summary>
	<brief_title>Safety Efficacy Study Budesonide ( Pulmicort® ) Turbuhaler® Japanese Children With Bronchial Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Patient complete precede Phase III study provide sign write informed consent patient 's legal representative Visit 1 4 week prior Visit 1 study . A signed write informed assent also obtain patient much possible When investigator obtain signed write informed consent Phase III study ( D5254C00769 ) patient 's legal representative , investigator also provide information study Respiratory infection , opinion investigator ( ) , may affect efficacy evaluation e.g. , low airway infection pneumonia , infection available effective antimicrobial drug deep seat mycosis Concurrent serious disease liver , kidney , heart complication , opinion investigator , may either put patient risk participation study , may influence result study , patient 's ability participate study . Any clinically relevant abnormal finding vital sign physical examination Visit 1 study , opinion investigator may put patient risk his/her participation study . Pregnant possible pregnancy plan become pregnant study period Other subject consider inappropriate participate study judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Bronchial</keyword>
</DOC>